Extended Data Fig. 8: A monoclonal anti-ACBP/DBI antibody prevents the manifestation of Cushing’s syndrome in male mice.
From: Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing’s syndrome
(a) Male C57BL/6J mice were treated with CORT (100 μg/mL) in drinking water (p.o.) for 5 weeks (n=10/group). (b) Plasma ACBP was quantified by ELISA (n=10/group). (c) Average food intake (n=3 cages/group) and (d) body weight (n=10 mice/group) were monitored. P-values compare areas under the curve. (e) The heatmap shows the standardized deviations (z-scores) of tissue weights relative to body weight and the quantification of various biochemical parameters across the treatment groups (n=10 mice/group). Statistical comparisons were performed by pairwise (two tailed) Wilcoxon test with FDR correction for multiple comparisons. (P-values are indicated). (f-i) Glucose tolerance tests (GTT) (n=10 mice/group) (f) and insulin tolerance tests (ITT) (n=10 mice/group) (h) were performed in the indicated groups. P-value refer to the comparison of areas under the curve (g,i). Statistical comparisons were performed by pairwise Wilcoxon tests with FDR correction for multiple comparison in the heatmaps. All dot plots depict means ± SEM. All curves were longitudinally analyzed with type II ANOVA and pairwise comparisons (c,d). One-way ANOVA with Tukey correction was used for statistical analysis (P-values are indicated) (d,g,i).
